Annovis Bio plans to raise approximately $6 million through a registered direct offering of 4 million shares at $1.50 each.
Quiver AI Summary
Annovis Bio, Inc., a company focusing on therapies for neurodegenerative diseases, has announced a registered direct offering of 4,000,000 shares of its common stock at $1.50 per share, anticipating gross proceeds of approximately $6 million. The offering is expected to close around October 13, 2025, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent for the offering, with proceeds intended for working capital and corporate purposes. The shares are being offered under a previously filed registration statement with the SEC. The company is committed to developing innovative treatments for conditions like Alzheimer’s and Parkinson’s diseases and has issued a disclaimer regarding the nature of this press release not constituting an offer to sell or buy securities.
Potential Positives
- Annovis Bio has successfully entered into definitive agreements for the purchase of 4,000,000 shares of its common stock, indicating strong interest and potential investor confidence in the company.
- The registered direct offering is expected to generate approximately $6 million in gross proceeds, providing the company with crucial funds for working capital and general corporate purposes.
- The securities are offered pursuant to an effective shelf registration statement, which streamlines the capital-raising process and enhances regulatory compliance.
Potential Negatives
- The company is raising funds through a stock offering at a low price of $1.50 per share, which may signal to investors that the company is in need of cash or is facing financial challenges.
- The necessity for a public stock offering may raise concerns among investors regarding the company’s ability to generate sufficient revenue from its operations, especially for a late-stage clinical drug platform.
- Forward-looking statements about the offering's consummation and the potential use of proceeds introduce uncertainty, reflecting risks that could negatively impact the company's future performance.
FAQ
What is Annovis Bio's recent stock offering announcement?
Annovis Bio announced a stock offering of 4,000,000 shares at $1.50 per share, aiming to raise approximately $6 million.
When is the closing date for the stock offering?
The closing of the offering is expected to occur on or about October 13, 2025, pending customary closing conditions.
Who is the placement agent for the offering?
H.C. Wainwright & Co. is acting as the exclusive placement agent for the registered direct offering.
What will Annovis Bio use the proceeds from the offering for?
The net proceeds from the offering are intended for working capital and general corporate purposes.
How can investors access the prospectus for the offering?
The prospectus will be filed with the SEC and can be obtained from H.C. Wainwright & Co. or on the SEC's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANVS Hedge Fund Activity
We have seen 21 institutional investors add shares of $ANVS stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP removed 166,219 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $360,695
- UBS GROUP AG removed 134,559 shares (-83.6%) from their portfolio in Q2 2025, for an estimated $291,993
- TWO SIGMA ADVISERS, LP removed 92,921 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $201,638
- MARSHALL WACE, LLP added 90,907 shares (+inf%) to their portfolio in Q2 2025, for an estimated $197,268
- VANGUARD GROUP INC added 48,844 shares (+7.5%) to their portfolio in Q2 2025, for an estimated $105,991
- WARBERG ASSET MANAGEMENT LLC removed 39,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $84,630
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 36,853 shares (+28.9%) to their portfolio in Q2 2025, for an estimated $79,971
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANVS Analyst Ratings
Wall Street analysts have issued reports on $ANVS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/30/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
To track analyst ratings and price targets for $ANVS, check out Quiver Quantitative's $ANVS forecast page.
$ANVS Price Targets
Multiple analysts have issued price targets for $ANVS recently. We have seen 2 analysts offer price targets for $ANVS in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Sumant Kulkarni from Canaccord Genuity set a target price of $17.0 on 09/30/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $10.0 on 09/03/2025
Full Release
MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof) in a registered direct offering. The closing of the offering is expected to occur on or about October 13, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be approximately $6 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering toward working capital and general corporate purposes.
The securities described above are being offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-276814), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. The offering is being made only by means of a prospectus supplement that forms a part of the registration statement. A prospectus supplement and an accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
[email protected]
